XHKG
0157
Market cap117mUSD
Sep 28, Last price
0.46HKD
Name
Natural Beauty Bio-Technology Ltd
Chart & performance
P/E
87.04
P/S
1.71
EPS
0.01
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
5.58%
Revenues
539m
+52.36%
Net income
11m
P
CFO
-26m
L+86.66%
Dividend
Jun 01, 20220.0235485 HKD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Natural Beauty Bio-Technology Limited (NBBTF) operates as an investment holding company, delivering a diverse range of skincare offerings and related services throughout the People's Republic of China, Taiwan, and other international regions. The company develops and markets an extensive selection of products under its "Natural Beauty" brand, which includes items for skincare, beauty, aromatherapy, cosmetics, health supplements, and make-up. Beyond its product lines, NBBTF provides various services such as specialized skin treatments, comprehensive beauty and spa experiences, medical cosmetology, professional skincare and beauty consulting, and training programs. Its spa facilities further enhance customer care by offering hydrotherapy, facial services, body treatments, and detailed skin analysis. Additionally, the company engages in the wholesale distribution of its beauty and skincare products. Natural Beauty Bio-Technology Limited was established in 1976 and is headquartered in Wan Chai, Hong Kong.
Key people
Yen Yu Tsai
Executive Chairwoman of the Board
Yen-Ling Lin
Chief Executive Officer · since 2018
Li-Ting Chen
Finance Vice President · since 2013
Qing Yi Liao
Operation Vice President · since 2014
Chien-Cheng Su
Executive Director · since 2011
Company Secretary · since 2019
Ming Ta Lee
Executive Vice Chairman of the Board · since 2009
Sh-Hsyu Su
Non-Executive Director · since 2013
Ruey-Long Chen
Independent Non-Executive Director · since 2010
Chi Chant Lu
Independent Non-Executive Director · since 2015
Non-Executive Independent Director · since 2018
IPO date
Mar 28, 2002
Employees
429
Domiciled in
HK
Incorporated in
KY
Valuation
Title HKD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||